Abstract 6062
Background
A standardized evaluation approach in oncology is essential to optimize treatment and management of patients. In particular, a medical software designed to provide standard metrics and reports may help the communication among health care professionals, facilitating the decision process. To this aim, a large survey study was conducted across the United Kingdom (UK), Spain (ES) and Italy (IT) exploring existing unmet needs and questioning the way oncological data is tracked in daily routine practice with the aim of offering some ideas for improvement.
Methods
Physicians were enrolled by an independent Market Research Company according to diiferent inclusion criteria: a) 2-35 years in practice; b) ≥50% of practice time in direct patient care; c) involvement in making treatment decisions ; d) involvement in ordering and reviewing tumour assessment reports; e) to be an investigator or author of an oncology clinical trial in the past 5 years.The study was conducted in November-December, 2018.
Results
A total number of 270 physicians (medical oncologists: n = 180, radio-oncologists: n = 90) participated (UK/100, ES/95, IT/75). The vast majority of physicians use Response Evaluation Criteria in Solid Tumors (RECIST) criteria in their daily practice (86%). Guidelines for response criteria for use in trials testing immunotherapeutics (iRECIST) and modified RECIST (mRECIST) are also used by between third and a quarter of physicians. Of note, almost half of the physicians indicated that there is a low level of data management in oncology and 2 out of 3 agree that this negatively impacts therapeutic decisions. Over a third of ES physicians believe that there is a low level of data management in oncology and a similar proportion in IT and ES report that it is impacting therapeutic decision making.
Conclusions
Only a third of physicians view their current reporting systems as adequate. All participants agree that any reporting system is in need of a common shared template for radiologists and oncologists. Thus, physicians identify a lack of consistency in diagnostic assessments and delays in receiving the reports as key unmet needs in tumor reporting systems –indicating the need for a streamlined system.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Wehealth Digital Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract